Loma Therapeutics Due Diligence

Run due diligence on Loma Therapeutics: check compliance and get alerts when suppliers or ownership change.

Denmark · owned by Independent (Denmark) · lomatherapeutics.com · 8 vendors

Loma Therapeutics is a Danish biotech startup developing a cutting-edge HPV-targeted immunotherapy (Loma001) to treat and prevent HPV-induced cancers, including head and neck, cervical, anal, and penile cancers. Their approach uses replication-deficient viral vectors to deliver full-length HPV antigens, triggering robust CD8+ T cell immune responses capable of targeting and eliminating HPV-infected and cancerous cells. The company is backed by the Danish Innovation Fund, BioInnovation Institute, and the European Commission's Women TechEU program, and is headquartered in Copenhagen, Denmark.

Resilience scores

Digital Sovereignty: 25
Digital Resilience: 5
Financial Resilience: 5

Technology vendors

Curanet A/S — Technology — Denmark
LiteSpeed Technologies, Inc. — Technology — United States
OpenJS Foundation — Technology — United States
and 5 more

Insights

Last updated 2026-09-13 · revision 2

8 direct vendors, 99 subvendors

Direct vendors by controlling owner country (sample)

United States: 6
Belgium: 1
United Kingdom: 1

Subvendors by controlling owner country (sample)

Denmark: 2
Belgium: 4
Australia: 2

Compliance

12 in-scope frameworks identified; showing 3.

Financials

Three-year financials

2025: gross profit DKK -483K, EBIT DKK -3.54M, equity DKK -8.12M
2024: gross profit DKK -2.04M, EBIT DKK -4.30M, equity DKK -4.58M

Financial Resilience Score: 5/10

Loma Therapeutics is an early-stage, pre-clinical Danish biotech spun out around 2023 with no commercial revenue and an expected negative operating result typical of research-stage ApS entities. Its financial position depends almost entirely on non-dilutive grant funding and incubator support rather than product cash flows, so traditional financial resilience metrics (revenue growth, EBIT, equity buffers) are not meaningful at this stage. That said, the company has demonstrated notable success in securing non-dilutive capital: two Innovation Fund Denmark Innobooster grants (most recent DKK 5M / ~€670K in June 2026), an Innovation Fund Denmark Grand Solutions grant with DTU and Rigshospitalet (June 2025), a European Commission Women TechEU grant (2024), and membership in the BioInnovation Institute Venture House Program (September 2024). Combined with a newly established board (Feb 2025) featuring experienced life-science operators and blue-chip scientific advisors including Dr. John T. Schiller (co-inventor of the HPV vaccine), the company appears well-positioned to raise an institutional Series A. However, cash-runway risk remains the dominant financial risk. The company is pre-revenue with a 6–10+ year path to potential product approval, has a single-modality pipeline (HPV adenoviral-vector immunotherapy), and faces meaningful clinical and regulatory binary risk. Overall resilience is moderate — strong for its stage due to grant traction and credible backers, but fundamentally fragile in absolute terms.

Key strengths: Multiple non-dilutive grants: two Innobooster grants (latest DKK 5M), Grand Solutions grant, Women TechEU grant, BioInnovation Institute (BII) Venture House Program membership providing infrastructure and seed capital, Blue-chip scientific advisors including Dr. John T. Schiller (NCI, HPV vaccine co-inventor) and Dr. David Curiel, Experienced board established Feb 2025 (Alejandra Mørk as Chair; Stuart Collinson, Ralf Wagner) signaling Series A readiness, Peer-reviewed publications in Cancer Immunology Research and Cancers providing external validation, Partnerships with DTU and Rigshospitalet

Risk factors: Pre-revenue, pre-clinical stage with no product cash flows expected for many years, Heavy reliance on grants and future equity rounds — cash-runway risk is dominant, Single-modality pipeline concentration (HPV vector immunotherapy), Competitive field with established players (ISA Pharmaceuticals, Nykode, Transgene, Inovio), Small team of ~7 with key-person dependency on founding scientists, Regulatory and clinical binary risk — first-in-human trial not yet initiated, Typical 6–10+ year clinical development timeline to potential approval

Revenue by geography

Denmark: 80%
European Union: 20%

Revenue by product/service

Loma001 (HPV-targeted adenoviral-vector immunotherapy): 100%

Workforce by country

Denmark: 7

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report